 Kimi Kondo
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiology | 4 | 2017 | 175 | 0.610 |
Why?
| | Lymphocele | 1 | 2013 | 2 | 0.400 |
Why?
| | Surgery, Computer-Assisted | 1 | 2013 | 84 | 0.360 |
Why?
| | Faculty | 1 | 2013 | 149 | 0.350 |
Why?
| | Curriculum | 4 | 2018 | 1060 | 0.350 |
Why?
| | Kidney Neoplasms | 4 | 2016 | 412 | 0.260 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 598 | 0.250 |
Why?
| | Kidney Transplantation | 1 | 2013 | 704 | 0.250 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1186 | 0.220 |
Why?
| | Clinical Competence | 1 | 2013 | 1244 | 0.210 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2016 | 38 | 0.210 |
Why?
| | Angiomyolipoma | 2 | 2016 | 21 | 0.210 |
Why?
| | Ultrasonography, Interventional | 2 | 2016 | 160 | 0.200 |
Why?
| | Diagnostic Imaging | 2 | 2016 | 339 | 0.180 |
Why?
| | Internship and Residency | 1 | 2013 | 1257 | 0.180 |
Why?
| | Students, Medical | 2 | 2017 | 375 | 0.160 |
Why?
| | Education, Medical, Undergraduate | 2 | 2018 | 207 | 0.140 |
Why?
| | Radiology, Interventional | 1 | 2018 | 49 | 0.130 |
Why?
| | Schools, Medical | 2 | 2018 | 157 | 0.130 |
Why?
| | Vena Cava Filters | 1 | 2017 | 64 | 0.120 |
Why?
| | Pregnancy, Abdominal | 1 | 2016 | 2 | 0.120 |
Why?
| | Thromboembolism | 1 | 2017 | 125 | 0.120 |
Why?
| | Radiology Information Systems | 1 | 2016 | 35 | 0.120 |
Why?
| | Biotechnology | 1 | 2016 | 46 | 0.120 |
Why?
| | Teaching | 1 | 2018 | 236 | 0.120 |
Why?
| | Laboratories | 1 | 2017 | 109 | 0.120 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 56 | 0.120 |
Why?
| | Organizational Innovation | 1 | 2016 | 120 | 0.120 |
Why?
| | Hypertension, Portal | 1 | 2016 | 66 | 0.110 |
Why?
| | Cavernous Sinus | 1 | 2015 | 16 | 0.110 |
Why?
| | Venous Insufficiency | 1 | 2015 | 12 | 0.110 |
Why?
| | Prosthesis Design | 1 | 2017 | 357 | 0.110 |
Why?
| | Venous Thrombosis | 1 | 2017 | 195 | 0.110 |
Why?
| | Methotrexate | 1 | 2016 | 240 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 244 | 0.110 |
Why?
| | Arteriovenous Fistula | 1 | 2015 | 38 | 0.110 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2015 | 53 | 0.110 |
Why?
| | Portal Vein | 1 | 2016 | 114 | 0.110 |
Why?
| | Personal Satisfaction | 1 | 2017 | 222 | 0.110 |
Why?
| | Radiography, Interventional | 1 | 2016 | 130 | 0.110 |
Why?
| | Radiology Department, Hospital | 1 | 2014 | 16 | 0.100 |
Why?
| | Hernia, Abdominal | 1 | 2013 | 8 | 0.100 |
Why?
| | Ascites | 1 | 2013 | 49 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 557 | 0.100 |
Why?
| | Hernia, Inguinal | 1 | 2013 | 43 | 0.100 |
Why?
| | Intestinal Obstruction | 1 | 2013 | 56 | 0.100 |
Why?
| | Embolization, Therapeutic | 1 | 2015 | 242 | 0.090 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2013 | 89 | 0.090 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 106 | 0.090 |
Why?
| | Translocation, Genetic | 1 | 2012 | 118 | 0.090 |
Why?
| | Radiography | 1 | 2013 | 845 | 0.080 |
Why?
| | Education, Medical | 1 | 2014 | 276 | 0.080 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 127 | 0.080 |
Why?
| | Treatment Outcome | 6 | 2016 | 11695 | 0.080 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2012 | 230 | 0.080 |
Why?
| | Disease Progression | 3 | 2013 | 2852 | 0.080 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2010 | 58 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 947 | 0.070 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 79 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2012 | 883 | 0.070 |
Why?
| | Piperazines | 1 | 2011 | 381 | 0.070 |
Why?
| | Neuroblastoma | 1 | 2010 | 174 | 0.070 |
Why?
| | Pyrazoles | 1 | 2012 | 510 | 0.070 |
Why?
| | Pyrimidines | 1 | 2011 | 533 | 0.070 |
Why?
| | Pyridines | 1 | 2012 | 605 | 0.060 |
Why?
| | Lung Neoplasms | 2 | 2012 | 2642 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2013 | 783 | 0.060 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2009 | 259 | 0.060 |
Why?
| | DNA Methylation | 1 | 2011 | 683 | 0.060 |
Why?
| | Anatomic Landmarks | 2 | 2016 | 31 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2012 | 970 | 0.060 |
Why?
| | United States | 4 | 2018 | 15988 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 6053 | 0.050 |
Why?
| | Aged | 5 | 2016 | 25947 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1182 | 0.050 |
Why?
| | Humans | 15 | 2018 | 144957 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2738 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2883 | 0.030 |
Why?
| | Young Adult | 4 | 2016 | 14126 | 0.030 |
Why?
| | Male | 6 | 2016 | 72406 | 0.030 |
Why?
| | Intergenerational Relations | 1 | 2017 | 18 | 0.030 |
Why?
| | Forecasting | 1 | 2018 | 391 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2011 | 1465 | 0.030 |
Why?
| | Inventions | 1 | 2016 | 19 | 0.030 |
Why?
| | Hemoperitoneum | 1 | 2016 | 12 | 0.030 |
Why?
| | Portography | 1 | 2016 | 7 | 0.030 |
Why?
| | Portal Pressure | 1 | 2016 | 4 | 0.030 |
Why?
| | Career Choice | 1 | 2018 | 237 | 0.030 |
Why?
| | History, 20th Century | 1 | 2017 | 325 | 0.030 |
Why?
| | Device Removal | 1 | 2017 | 143 | 0.030 |
Why?
| | Pregnancy, Ectopic | 1 | 2016 | 53 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2016 | 141 | 0.030 |
Why?
| | Models, Organizational | 1 | 2016 | 144 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2016 | 95 | 0.030 |
Why?
| | Female | 8 | 2016 | 78376 | 0.030 |
Why?
| | Operative Time | 1 | 2016 | 175 | 0.030 |
Why?
| | Fluoroscopy | 1 | 2016 | 176 | 0.030 |
Why?
| | Radiation Exposure | 1 | 2016 | 63 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2016 | 146 | 0.030 |
Why?
| | Program Development | 1 | 2017 | 370 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2016 | 193 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 508 | 0.030 |
Why?
| | Carbon Dioxide | 1 | 2016 | 242 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 2016 | 288 | 0.020 |
Why?
| | Time Factors | 2 | 2016 | 7183 | 0.020 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 63 | 0.020 |
Why?
| | Adult | 5 | 2016 | 40506 | 0.020 |
Why?
| | Retrospective Studies | 3 | 2016 | 17101 | 0.020 |
Why?
| | Contrast Media | 1 | 2016 | 488 | 0.020 |
Why?
| | Program Evaluation | 1 | 2017 | 949 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 529 | 0.020 |
Why?
| | Ultrasonography | 1 | 2016 | 770 | 0.020 |
Why?
| | Bile Duct Neoplasms | 1 | 2013 | 128 | 0.020 |
Why?
| | Genes, Neoplasm | 1 | 2011 | 25 | 0.020 |
Why?
| | Laparoscopy | 1 | 2016 | 475 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1835 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2011 | 77 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 635 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2011 | 56 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2012 | 183 | 0.020 |
Why?
| | Adolescent | 3 | 2016 | 22453 | 0.020 |
Why?
| | ras Proteins | 1 | 2012 | 151 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 253 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 966 | 0.020 |
Why?
| | Reoperation | 1 | 2013 | 631 | 0.020 |
Why?
| | Middle Aged | 4 | 2016 | 35928 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 224 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1990 | 0.020 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2012 | 211 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 862 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 758 | 0.020 |
Why?
| | Nephrectomy | 1 | 2010 | 158 | 0.020 |
Why?
| | Genome, Human | 1 | 2011 | 422 | 0.020 |
Why?
| | Risk Factors | 2 | 2013 | 10792 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 695 | 0.020 |
Why?
| | Kidney | 1 | 2016 | 1496 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 629 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 623 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 824 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1839 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1385 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 343 | 0.020 |
Why?
| | Cisplatin | 1 | 2009 | 334 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1540 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3415 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1619 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 2882 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2016 | 6434 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4564 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3550 | 0.010 |
Why?
| | Pregnancy | 1 | 2016 | 7191 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 1141 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 8279 | 0.010 |
Why?
| | Infant | 1 | 2016 | 10039 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 11799 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 4293 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 4099 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1958 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 2197 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3869 | 0.010 |
Why?
| | Child | 1 | 2016 | 22657 | 0.010 |
Why?
|
|
Kondo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|